Dyne Therapeutics, Inc. (DYN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put DYN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 30%, softest on share dilution.
View QualityThis stock is volatile — it swings about 2% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskDYN's growth depends on advancing its clinical pipeline, particularly DYNE-302 in FSHD. Revenue growth has been weak, with the latest quarter missing expectations. DYN trades at a valuation that implies a price about 49% above where it currently trades, suggesting it looks cheap on this basis. The risk lies in management's unsteady performance and the potential for further guidance cuts, with a 38% probability of missing outlooks. Peer multiples imply a price about 49% above where it trades. Our read is provisional.
Trailing returns as of 2026-09-14. DYN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering DYN (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for DYN in the last 4 months.
Continue this research
Compare DYN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DYN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put DYN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Novartis trial failure impacts competitive landscape for DYN.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $18.52
The last 12 months of price, then the range of analyst 12-month targets from today’s $18.52.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Threatens: Advance clinical pipeline including DYNE-302 in FSHD
Price target cut indicates increased risk in clinical pipeline.

Rival drug failure may impact market dynamics.

Advances: Launch z-rostudirsen in DMD by Q1 2027
Phase 1/2 trial enrollment supports z-rostudirsen launch timeline.
Advances: Launch z-rostudirsen in DMD by Q1 2027
Key regulatory milestone enhances z-rostudirsen launch prospects.
Advances: Launch z-rostudirsen in DMD by Q1 2027
BLA submission is critical for z-rostudirsen launch.

Advances: Launch z-basivarsen in Q1 2028
Phase 3 trial milestone supports z-basivarsen development.